Genta reports positive endpoints in Genasense melanoma trial

By Elaine Rigoli

Tampa, Fla., Sept. 15 - Genta, Inc. said results from the phase 3 trial of Genasense (oblimersen sodium) injection in patients with advanced melanoma suggest that Genasense can be a major addition to chemotherapy for patients with this disease, with a side-effect profile that is highly manageable.

Genasense, the Berkeley Heights, N.J., biopharmaceutical company's lead anticancer drug, is a novel targeted therapy that blocks the production of Bcl-2, a protein that appears to be a fundamental cause of resistance to cancer treatment.

By knocking down Bcl-2 in cancer cells, the company said Genasense may enhance the effectiveness of chemotherapy in patients with advanced melanoma.

The long-term follow-up has confirmed the trends that were observed in the earlier analyses, officials noted, adding that this was the first trial to achieve such a broad array of positive endpoints.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.